Better mind the gap: Addressing the shortage of HIV-positive women in clinical trials

AIDS

Volumn 24, Issue 8, 2010, Pages 1091-1094

  D'Arminio Monforte, Antonella ^a   González, Lorena ^b   Haberl, Annette ^c   Sherr, Lorraine ^d   Ssanyu Sseruma, Winnie ^e   Walmsley, Sharon L ^f,g  

^a SAN PAOLO HOSPITAL   (Italy)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e CHRISTIAN AID   (United Kingdom)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; THYMIDINE DERIVATIVE;

BODY SIZE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFIDENTIALITY; CONTRACEPTION; CULTURAL ANTHROPOLOGY; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LANGUAGE; LIPODYSTROPHY; MEDICAL SOCIETY; NOTE; PATIENT ADVOCACY; PREGNANCY; PRIORITY JOURNAL; PUBLICATION; RASH; SAMPLING; SEX DIFFERENCE; TREATMENT OUTCOME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PATIENT PARTICIPATION; PATIENT SELECTION; PREGNANCY;

EID: 77951880542     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283390db3     Document Type: Note

References (18)

1. UNAIDS. Report on the global AIDS epidemic; 2008. http://www.unaids.org/ en/KnowledgeCentre/HIVData/GlobalReport/2008/2008-Global-report.asp.
2. Floridia M, Giuliano M, Palmisano L, Vella S. Gender differences in the treatment of HIV infection. Pharmacol Res 2008; 58:173-182.
3. Nicastri E, Leone S, Angeletti C, Palmisano L, Sarmati L, Chiesi A, et al. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother 2007; 60:724-732. (Pubitemid 47439674)
4. Struble K, Soon G, Min M, Chan-Tack K, Murray J, Birnkrant D, et al. Meta-analysis of efficacy outcomes for treatment-nä?ve and treatment experienced HIV-infected women in randomized controlled clinical trials (2000-2008). 16th Conference on Retroviruses and Opportunistic Infections; Montréal; 8-11 February 2009; poster 987b.
5. Merkatz RB, Temple R, Sobel S, Feiden K, Kessler DA, for The Working Group on Women in Clinical Trials. Women in clinical trials of new drugs: a change in food and drug administration policy. N Engl J Med 1993; 329:292-296.
6. UNAIDS. Making HIV trials work for women and adolescent girls; 2007. http://data.unaids.org/pub/BrochurePamphlet/2008/JC1605-hiv-trials-brochure-en. pdf.
7. Rathore SS, Wand Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347:1403-1411.
8. Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gender Med 2007; 4:106-119. (Pubitemid 47248489)
9. Collazos J, Asensi V, Carton JA. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. AIDS 2007; 21:835-843. (Pubitemid 46573155)
10. Kuyper LM, Wood E, Montaner JS, Yip B, O'connell JM, Hogg RS. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-infected patients in a population-based cohort. J Acquir Immune Defic Syndr 2004; 37:1470-1476. (Pubitemid 39602337)
11. Herrington DM. Hormone replacement therapy and heart disease: replacing dogma with data. Circulation 2003; 107:2.
12. Clark R. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf 2005; 28:1075-1083. (Pubitemid 41775999)
13. Pernerstorfer-Schoen H, Jilma B, Perschler A, Wichlas S, Schindler K, Schindl A, et al. Sex differences in HAART-asso-ciated dyslipidaemia. AIDS 2001; 15:725-734.
14. Currier JS, Spino C, Grimes J, Wofsy CB, Katzenstein DA, Hughes MD, et al. Differences between women and men in adverse events and CD4R responses to nucleoside analogue therapy for HIV infection. The AIDS Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr 2000; 24:316-324.
15. Mazhude C, Jones S, Murad S, Taylor C, Easterbrook P. Female sex but not ethnicity is a strong predictor of nonnucleoside reverse transcriptase inhibitor-induced rash. AIDS 2002; 16:1566-1568. (Pubitemid 34804228)
16. Bonfanti P, Gulisano C, Ricci E, Timillero L, Valsecchi L, Carradori S, et al. Risk factors for lipodystrophy in the CISAI cohort. Biomed Pharmacother 2003; 57:422-427. (Pubitemid 37494717)
17. MoherD,Schulz KF, Altman DG, for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357:1191-1194; http://www.consort-statemen-t.org/. (Pubitemid 32378696)
18. UNAIDS Policy Brief. The greater involvement of people living with HIV (GIPA); March 2007. http://www.unaids.org/en/PolicyAndPractice/GIPA/default.asp.